European Journal of Cancer 2012-01-01

Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study

Seung Tae Kim, Jung Hun Kang, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, In Gyu Hwang, Sang-Cheol Lee, Keon-Woo Park, Hyo Rak Lee, Won Ki Kang

文献索引：Eur. J. Cancer 50(16) , 2822-30, (2014)

全文：HTML全文

摘要

Purpose We aimed to the addition of synthetic 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin to capecitabine–cisplatin (XP) in patients with previously untreated advanced gastric cancer (AGC).